Amongst the various routes of drug delivery , oral route is perhaps the most preferred to the patient and the clin ician alike because oral mucosa is relat ively permeab le with a rich blood supply, it is robust and shows short recovery times after stress or damage 1-4 , and the virtual lack of Langerhans cells 5 makes the oral mucosa tolerant to potential allergens. Within the oral mucosal cavity, the buccal region offers an attractive route of administration for systemic drug delivery of potent peptide and perhaps protein drug molecules. The mucosa has a rich blood supply and it is relatively permeable.
Buccal delivery involves the administration of the desired drug through the buccal mucosal memb rane lining of the oral cavity. Unlike oral d rug delivery, which presents a hostile environ ment for d rugs, especially p roteins and polypeptides, due to acid hydrolysis and the hepatic firstpass effect, the mucosal lin ing of buccal tissues provides a much milder environ ment for drug absorption. Additionally, buccal drug delivery has a high patient acceptability co mpared to other non-oral routes of drug administration. Harsh environmental factors that exist in oral delivery of a d rug are circu mvented by buccal delivery. Avoiding acid hydrolysis in the gastrointestinal (GI) tract and bypassing the first-pass effect are some of the advantages of this route of drug delivery. Moreover, rapid cellular recovery and achievement of a localized site on the smooth surface of the buccal mucosa are among the other advantages of this route of drug delivery.
The disadvantages associated with this route of drug delivery are the low permeability of the buccal memb rane 6 , specifically when co mpared to the sublingual membrane 7, 8 , and a smaller surface area. The total surface area of the memb ranes of the oral cavity available for drug absorption is 170 cm2 5 , of which ~50 cm2 represents non-keratinized tissues, including the buccal membrane 9 . The continuous secretion of saliva (0.5-2 l/day) leads to subsequent dilution of the drug 8 . Swallo wing of saliva can also potentially lead to the loss of dissolved or suspended drug and, ultimately, the involuntary removal of the dosage form. These are some of the problems that are associated with buccal drug delivery. Success of buccal drug delivery system based on the selection of proper excip ients and taking consideration of factors affecting buccal drug delivery i.e. physiological propert ies of drug, pathological state of patient and the polymer related factors etc. Thus present focuses on the various perspectives of buccal drug delivery which are necessary to consider before designing any dosage form. The rev iew also assesses the polymers used in buccal drug delivery as well as various factors affecting buccal adhesive drug delivery systems.
STRUCTURE OF THE ORAL MUCOSA
The oral mucosa is composed of an outermost layer of stratified squamous epitheliu m. Belo w this lies a basement memb rane, a lamina propria follo wed by the submucosa as the innermost layer. The ep itheliu m is similar to stratified squamous epithelia found in the rest of the body in that it has a mitotically active basal cell layer, advancing through a number of differentiating intermediate layers to the superficial layers, where cells are shed from the surface of the epithelium 10 . The epithelium of the buccal mucosa is about 40-50 cell layers thick, while that of the sublingual epitheliu m contains somewhat fewer. The ep ithelial cells © 2011, JDDT. All Rights Reserved ISSN: 2250-1177 increase in size and become flatter as they travel fro m the basal layers to the superficial layers. The oral mucosal thickness varies depending on the site: the buccal mucosa measures at 500-800 µm, while the mucosal thickness of the hard and soft palates, the floor of the mouth, the ventral tongue, and the gingivae measure at about 100-200 µm. The composition of the epitheliu m also varies depending on the site in the oral cavity. The mucosae of areas subject to mechanical stress (the gingivae and hard palate) are keratinized similar to the epidermis. The mucosae of the soft palate, the sublingual, and the buccal regions, however, are not keratinized. The keratin ized epithelia contain neutral lipids like ceramides and acylceramides which have been associated with the barrier function. These epithelia are relatively impermeab le to water. In contrast, non-keratinized epithelia, such as the floor of the mouth and the buccal epithelia, do not contain acylceramides and only have small amounts of ceramide [11] [12] [13] . They also contain small amounts of neutral but polar lip ids, main ly cholesterol sulfate and glucosyl ceramides. These epithelia have been found to be considerably more permeab le to water than keratin ized epithelia [10] [11] [12] .
DRUG DELIVERY PATHWAY THROUGH B UCCAL MUCOSA:
The main mechanis ms responsible for the penetration of various substances include simple diffusion (paracellular, transcellular), carrier-med iated diffusion, active transport, and pinocytosis or endocytosis. Recent evidence has shown that passive diffusion is the primary mechanis m for the transport of drugs across the buccal mucosa, although carrier-mediated transport has been reported to have a small ro le. Two routes of passive transport are available in the buccal epitheliu m; one involves the transport of compounds through the intercellular spaces between the cells (paracellular), and the other involves passage into and across the cells (transcellular). Depending on the nature of the permeant, i.e. the overall mo lecular geo metry, lipophilicity, and charge, either of the transport pathways across buccal epitheliu m can be selected.
While considerable evidence has been presented to document that most compounds diffuse through the buccal mucosa by passive diffusion or simple Fickian diffusion 14 , some are transported by a carrier mediated process across the buccal mucosa. Glucose 15 , monocarboxylic acids and salicylic acid 16, 17 , and nicotinic acid 18, 19 , are examples of substances which utilize a carrier-mediated diffusion mechanis m for permeat ion across buccal epitheliu m. 
LOCAL AND S YSTEMIC DRUG DELIV ERY VIA THE ORAL MUCOSA
Absorption of drug via the mucous memb ranes of the oral cavity can occur in either the sublingual, buccal, or local regions. The local region includes all areas other than the former two regions. The oral mucosa is classified as a somewhat leaky epitheliu m with a permeability rank order of sublingual, buccal, palatal, based on the thickness and degree of keratinization of the tissues 7 . Different regions of the oral cav ity vary greatly in terms of their co mposition and their potential utility in drug delivery. The thin and highly permeable membrane of the sublingual tissue is a perfect target if a prompt onset is desired. Considerable surface area and high blood flow to this region provide a means for rapid access to the systemic circulation. However, if a retentive, sustained-release system is desired, the sublingual memb rane fails to be an appropriate target tissue.
Sustained-release systems, wh ich are able to provide sustained drug concentrations in the systemic circulat ion due to delayed release of the drug fro m the formu lation, are suitable dosage forms for the buccal region of the oral cavity. The lower permeability of th is region co mpared to the sublingual site is ideal for controlled-release systems. Additionally, drug delivery via this site avoids extensive enzy me degradation and first-pass metabolism seen with oral admin istrations, which are desired outcomes for the delivery of therapeutic proteins and peptides. However, the low permeab ility of this site is not always an attractive feature and, depending on the choice of drug, can be a major limitation. Use of sub-toxic levels of penetration enhancers and targeted delivery may potentially overcome this problem in the buccal reg ion of the oral cav ity.
Local delivery in the oral cavity has had particular applications in the treatment of toothache, periodontal diseases, and bacterial infections. Ho wever, because of its specificity, local delivery does not have the broad range of applications that sublingual and buccal drug administration provides. 20 :
MECHANIS M OF MUCOADHES ION

Hydration mediated adhesion:
Certain hydrophilic poly mers have the tendency to imbibe large amount of water and become sticky, thereby acquiring bioadhesive properties.
Bonding mediated adhesion:
For adhesion to occur, mo lecules must bond across the interface. These bonds can arise in the following way.
 Ionic bonds  Covalent bonds  Hydrogen bonds  Vander-Waals bonds  Hydrophobic bonds
POLYMERS IN B UCCAL ADHES IVE DRUG DELIVERY
Mucoadhesive delivery systems are being explored fo r the localization of the active agents to a particular location/ site. Polymers have played an important role in designing such systems so as to increase the residence time of the active agent at the desired location. Polymers used in mucosal delivery system may be of natural or synthetic origin.
Hydrophilic pol ymers
The polymers within this category are soluble in water. Matrices developed with these polymers swell when put into an aqueous media with subsequent dissolution of the matrix. The polyelectrolyte extends greater mucoadhesive property when compared with neutral polymers 21 . Anionic polyelectrolytes, e.g. poly (acrylic acid) and carboxy methyl cellulose, have been extensively used for designing mucoadhesive delivery systems due to their ability to exhibit strong hydrogen bonding with the mucin present in the mucosal layer 22, 23 . Chitosan provides an excellent examp le of cationic polyelectro lyte, which has been extensively used for developing mucoadhesive polymer due to its good biocompatibility and biodegradable properties 24 . Chitosan undergoes electrostatic interactions with the negatively charged mucin chains thereby exh ibiting mucoadhesive property 21 . The ionic polymers may be used to develop ionic complex with the counter-ionic drug mo lecules so as to have a drug delivery matrix exhib iting mucoadhesive property. Mucoadhesive microcapsules can be designed with same principle by using orifice-ionic gelation method. Non-ionic polymers, e.g. polo xamer, hydro xypropyl methyl cellu lose, methyl cellu lose, poly (vinyl alcohol) and poly (vinyl pyrrolidone), have also been used for mucoadhesive properties 21 . Cellu lose and its derivates have been reported to have surface active property in addition to its film forming capability 24, 25 . Cationic cellu lose derivatives (e.g. cationic hydroxyethyl celluloses) have been used in conjunction with various anionic polymers for the development of mucoadhesive sustained delivery systems 21, 26 .
Hydrogels
Hydrogels can be defined as three-dimensionally cross lin ked polymer chains which have the ability to hold water within its porous structure due to the presence of hydrophilic functional groups like hydro xyl, amino and carboxy l groups. In general, with the increase in the cross lin king density there is an associated decrease in the mucoadhesion 27 . Thielmann et al. reporteds the thermal cross linking of poly (acrylic acid) and methyl cellu lose. They reported that with the increase in the cross linking density, there was a reduction in the solubility parameters and swelling which resulted in a reduction of mucoadhesion 27 .
Thi olated pol ymers:
The presence of free thiol groups in the polymeric skeleton helps in the formation of disulphide bonds with that of the cysteine-rich sub-domains present in mucin which can substantially imp rove the mucoadhesive properties of the polymers (e.g. poly (acry lic acid ) and chitosan) in addition to the paracellular uptake of the bioactive agents 28 -32 . Various thiolated polymers include chitosaniminothiolane, poly (acrylic acid)-cysteine, poly (acrylic acid)-homocysteine, chitosan-thioglycolic acid, chitosanthioethylamid ine, alg inate-cysteine, poly (methacrylic acid)-cysteine and sodium carbo xy methylcellu losecysteine 22 .
Lectin-based polymers:
Lectins are proteins which have the ability to reversibly bind with specific sugar / carbohydrate residues and are found in both animal and plant kingdom in addit ion to various microorganis ms 33 -35 . Many lectins have been found to be toxic and immunogenic which may lead to systemic anaphylaxis in susceptible individuals on subsequent exposure 22 . The specific affinity of lectins towards sugar or carbohydrate residues provides them with specific cytoadhesive property and is being explored to develop targeted delivery systems. The various lectins which have shown specific binding to the mucosa include lectins extracted fro m Ulex europaeus I, soybean, peanut and Lens culinarius 36 .
FACTORS AFFECTING MUCOADHES ION IN THE B UCCAL CAVITY
A variety of factors affect the mucoadhesion in the buccal cavity are discussed below:
Polymer -related factors
Molecular weight
In general, it has been shown that the bioadhesive strength of a polymer increases with molecu lar weights above 100,000 8. As one examp le, the direct correlation between the bioadhesive strength of polyoxyethylene polymers and their molecu lar weights, in the range of 200,000 to 7,000,000, has been shown by Tiwari et al. 37 
Flexibility
Bioadhesion starts with the diffusion of the poly mer chains in the interfacial reg ion. Therefore, it is important that the polymer chains contain a substantial degree of flexib ility in order to achieve the desired entanglement with the mucus. In general, mobility and flexib ility of poly mers can be related to their viscosities and diffusion coefficients, where higher flexib ility of a poly mer causes greater diffusion into the mucus network 38 .
Hydrogen bonding capacity
Hydrogen bonding is another important factor in mucoadhesion of a polymer. Park and Robinson found that in order for mucoadhesion to occur, desired polymers must have functional groups that are able to form hydrogen bonds 39 . They have also confirmed that flexibility of the poly mer is important to improve this hydrogen bonding potential. Poly mers such as poly(vinyl alcohol), hydro xylated methacrylate, and poly(methacrylic acid ), as well as all their copolymers, are poly mers with good hydrogen bonding capacity 10 . 
Cross-linking density
The average pore size, the number average molecu lar weight of the cross-linked poly mers, and the density of cross-linking are three important and interrelated structural parameters of a poly mer network 59 . Therefore, it seems reasonable that with increasing density of cross-linking, diffusion of water into the polymer network occurs at a lower rate which, in turn, causes an insufficient swelling of the poly mer and a decreased rate of interpenetration between polymer and mucin 38 . Flory has reported this general property of polymers, in which the degree of swelling at equilibriu m has an inverse relationship with the degree of cross-linking of a poly mer 40 .
Charge on polymer
Some generalizations about the charge of bioadhesive polymers have been made previously, where nonionic polymers appear to undergo a smaller degree of adhesion compared to anionic polymers. Peppas and Buri have demonstrated that strong anionic charge on the polymer is one of the required characteristics for mucoadhesion 10 . It has been shown that some cationic polymers are likely to de monstrate superior mucoadhesive properties, especially in a neutral or slightly alkaline med iu m 41 . Additionally, some cationic high-molecular-weight poly mers, such as chitosan, have shown to possess good adhesive properties.
Concentration
The importance of this factor lies in the development of a strong adhesive bond with the mucus, and can be explained by the polymer chain length available for penetration into the mucus layer. When the concentration of the polymer is too low, the number of penetrating polymer chains per unit volume of the mucus is small, and the interaction between polymer and mucus is unstable 9 . In general, the more concentrated polymer would result in a longer penetrating chain length and better adhesion. However, for each polymer, there is a critical concentration, above which the polymer produces an © 2011, JDDT. All Rights Reserved ISSN: 2250-1177 -unperturbed‖ state due to a significantly coiled structure. As a result, the accessibility of the solvent to the polymer decreases, and chain penetration of the polymer is drastically reduced. Therefore, higher concentrations of polymers do not necessarily imp rove and, in some cases, actually diminish mucoadhesive properties. One of the studies addressing this factor demonstrated that high concentrations of flexible polymeric films based on polyvinylpyrrolidone or poly (vinyl alcohol) as film-forming poly mers did not further enhance the mucoadhesive properties of the polymer 42 .
Hydration (swelling):
Hydration is required for a mucoadhesive polymer to expand and create a proper -macro molecular mesh‖ of sufficient size, and also to induce mob ility in the polymer chains in order to enhance the interpenetration process between polymer and mucin 38 . Polymer swelling permits a mechanical entanglement by exposing the bioadhesive sites for hydrogen bonding and/or electrostatic interaction between the polymer and the mucous network 38 .
However, a critical degree of hydration of the mucoadhesive polymer exists where optimu m swelling and bioadhesion occurs 10 .
Initial contact time:
The initial contact time between mucoadhesive and the mucus layer determines the extent of swelling and the interpenetration of polymer chains. Although with the initial pressure the initial contact time can dramatically affect the performance of a system the mucoadhesive strength increases as the initial contact time increases. 43 
Environmental factors
The mucoadhesion of a polymer not only depends on its mo lecular properties, but also on the environmental factors adjacent to the polymer. Saliva, as a dissolution mediu m, affects the behavior of the polymer. Depending on the saliva flow rate and method of determination, the pH of this mediu m has been estimated to be between 6.5 and 7.5. The residence time of dosage forms is limited by the mucin turnover time, which has been calculated to range [ and 270 min in rats 44 and 12-24 h in hu mans 45 .
Figure 4: effect of mucosal environ ment on mucoadhesion
Movement of the buccal tissues while eating, drin king, and talking, is another concern which should be considered when designing a dosage form for the oral cavity. Movements within the oral cav ity continue even during sleep, and can potentially lead to the detachment of the dosage form. Therefore, an optimu m time span for the administration of the dosage form is necessary in order to avoid many of these interfering factors 46 .
Physiological Variables
Applied strength:
To place a solid bioadhesive system, it is necessary to apply a defined strength. The adhesive strength increases with the applied strength or with the density of its application up to an optimu m. The pressure initially applied to the mucoadhesive tissue contact site can affect the depth of interpenetration. If h igh pressure is applied for a satisfactory longer period of time poly mers become mucoadhesive even though they do not have attractive interaction with mucins 43, 47 .
Secretion of the model substrate surface:
Since physical and biological changes may occur in the mucus gels on tissues under experimental conditions, the variability of biological substrate should be confirmed by examining properties like permeability, electro physiology, or histology etc. Such studies may be necessary before and after preparing the in vitro tests using tissues for the better in vitro / in vivo correlation. 48, 49 
Disease state:
The physicochemical properties of the mucus are known to change during disease conditions such as common cold, gastric ulcers, u lcerative colitis, cystic fibrosis, bacterial and fungal infections of the female reproductive tract and inflammatory conditions of the eye. The exact structural changes taking place in mucus under these conditions are not clearly understood. If mucoadhesive are to be used in the diseased state, the mucoadhesive property needs to be evaluated under it. 43, 48 
ADVANTAGES OF B UCCAL ADHES IVE DRUG DELIVERY S YS TEM 50, 51
1. Ease of ad ministration.
2. Systemic absorption is rapid. 3. The buccal mucosa is highly perfused with blood vessels and offers a greater permeability than the skin. 4. Permits localizat ion of drug to the oral cavity for a prolonged period of time. 5. Can be ad min istered to unconscious patients. 6 . Offers an excellent route, for the systemic delivery of drugs with high first pass metabolis m, thereby offering a greater bioavailability. 7. Reduction in dose results reducing dose related side effects. 8. Drugs which destroyed by enzymatic, alkaline or acidic environment can be ad min istered by this route. 9. Drugs with poor b ioavailability via the oral route can be administered conveniently. 10. It offers a passive system of drug absorption and does not require any activation. 11. The presence of saliva ensures relatively large amount of water for drug dissolution. 12. This route provides an alternative for the administration of various hormones, narcotic analgesic, steroids, enzymes, cardiovascular agents etc. 13. Termination of therapy is easy.
LIMITATIONS OF B UCCAL ADHES IVE DRUG ADMINIS TRATION 50, 51
Drugs, which irritate the oral mucosa, haves unpleasant taste/odor, cannot be administered by this route.
1. Drugs which are unstable at buccal pH cannot be administered by this route. 2. Only drugs with small dose requirements can be administered. 3. Drugs may swallow with saliva and loses the advantages of buccal route. 4. Only those drugs, which are absorbed by passive diffusion, can be ad min istered by this route. 5. Swallo wing of the formulat ion by the patient may be possible.
GEN ERAL CONSIDERATIONS IN DES IGNING OF B UCCAL DOSAGE FORMS
Physiological aspects/Role of Saliva and Mucus:
Constant flow of saliva and mobility of the involved tissues challenge drug delivery to the oral cavity. The residence time of drugs delivered to the oral cavity is typically short, in the range of 5-10 min 9 . Buccal mucoadhesive formulations are expected to overcome this problem. Bioadhesive polymers offer a means by which a delivery system is attached to the buccal mucosa, and hence, provide substantially longer retention times at the absorption site. They also provide a means to confine and maintain high local concentrations of the drug and/or excip ient(s) to a defined, relatively small region of the mucosa in order to minimize loss to other regions and limit potential side effects.
The buccal mucosa is a very suitable region for bioadhesive system application because of its smooth and relatively immobile surface, as well as direct accessibility. However, there are some inherent limitations associated with buccal drug delivery, including short residence time, small absorption area, and barrier properties of the buccal mucosa. The size of a buccal dosage form is restricted by the very limited area availab le for applicat ion of the delivery system.
This size restriction, in turn, limits the amount of drug that can be incorporated in the dosage forms. In general, a buccal delivery device that is 1-3 cm 2 in size 52 and a drug with a daily dose requirement of 25 mg or less 7 would be preferred. In addition, an ellipsoid shape appears to be most acceptable 52 , and the thickness of buccal delivery devices is usually limited to a few millimeters 53 .
The mucus layer covering the buccal mucosa is necessary for bioadhesive systems. Unfortunately, it not only forms a physical barrier to drug permeation, but also prevents longterm bioadhesion and sustained drug release by its short turnover time. Interestingly, the presence of bioadhesive polymers on a mucous membrane might alter the turnover of mucin, since the residence time o f mucoadhesives are usually longer than the reported mucin turnover time 9 . Nevertheless, the maximu m duration for buccal drug delivery is usually limited to approximately 4-6 h, since meal intake and/or drinking may require dosage form removal 54 .
Pathological aspects:
Many diseases can affect the thickness of the epitheliu m, resulting in alterat ion of the barrier property of the mucosa. So me d iseases or treatments may also influence the secretion and properties of the mucus 55 , as well as the saliva. Changes at the mucosal surface due to these pathological conditions may complicate the application and retention of a bioadhesive delivery device. Therefore, understanding the nature of the mucosa under relevant disease conditions is necessary for designing an effective buccal delivery system. In addit ion, drugs with the potential of changing the physiological conditions of the oral cavity may not be suitable for buccal delivery. 
Pharmacological aspects:
A buccal dosage form may be designed to deliver a drug to the systemic circulation, or merely indicated for local therapy of the oral mucosa. Select ion of dosage forms is affected by the intended application, target site of action, drug characteristics, and the site to be treated (periodontal pockets, gingival, teeth, buccal mucosa, or systemic).
Pharmaceutical aspects:
Factors affecting both drug release and penetration through buccal mucosa must also be considered in the formulat ion design. In addition to the physicochemical characteristics required for desirable drug release and absorption, organoleptic properties of the drug or the delivery device should also be considered, since the buccal delivery systems are to be exposed to a highly developed sensory organ.
A. Selection of drug:
Poor drug solubility in saliva could significantly retard drug release fro m the dosage form. Various solubilizers have been used to solubilized and increase the absorption of poorly water-soluble drugs delivered via the buccal mucosa.
Criteria for selection of drug for buccal adhesive deli very:
1. Drugs those are primarily absorbed in buccal cavity; 2. Drugs those are easily permeate through buccal mucosa 3. Drugs those degrade in the G.I.T. 4. Drugs acting locally in the buccal cavity; 5. Drugs which are absorbed by passive diffusion 6. Drug those have small dose are suitable.
B. Selection of formulation excipients
Selection of formu lation excipients is yet another important consideration, since acidic co mpounds can stimulate the secretion of saliva, which enhances not only drug dissolution, but also drug loss by involuntary swallowing. Besides, addition of a separate additive for each function could complicate and enlarge the dosage form, which might be problematic for buccal applications. Therefore, as mentioned previously, polymers with mu ltip le functions seem pro mising.
C. Permeation Enhancers:
Permeability characteristics of the buccal mucosa may be continually changed by the rapid turnover of the buccal epitheliu m (3-8 days compared to about 30 days for the skin 8 ). Generally, the buccal mucosa is considerably less permeab le, and hence, does not provide rapid absorption and good bioavailability seen with sublingual administration. Permeab ility of the buccal mucosa can be increased by various penetration enhancers capable of increasing cell memb rane fluidity, ext racting the structural intercellular and/or intracellu lar lipids, altering cellu lar proteins, or altering mucus structure and rheology 56 .
Incorporation of unsaturated fatty acids into the mucoadhesive polymers has been shown to be effective in buccal delivery of drugs. The mechanism for the permeab ility enhancement by unsaturated fatty acids is through increasing the fluidity of the membrane phospholipids. This class of permeation enhancers reversibly alters the physical structure of the membrane by incorporating themselves into the phospholipid membrane. 
D. Enzyme Inhibition:
Even though the enzyme activity in the buccal mucosa is relatively low and, as a result, drug inactivation is slower and less extensive than in other mucosal routes 57 , susceptible drugs, especially peptides and proteins, can still be degraded by the enzymes in saliva and buccal mucosa. Therefore, enzy me inhibitors may be incorporated in the dosage forms to increase drug bioavailability. some bioadhesive polymers, such as poly(acrylic acid), polycarbophil, and carbopol, can also inhibit certain proteolytic enzymes (trypsin, a-chymotrypsin, carboxypeptidases A and B, and leucine aminopeptidase) 58 . However, cysteine protease (pyroglutamyl aminopeptidase) may not be inhibited by polycarbophil and carbopol 58 .
E. pH of Formulation
Maximal permeation occurs at the pH at which these drugs are predominantly in the unionized fo rm. Control of pH is critical for successful buccal delivery of ionizab le drugs.
Saliva has a weak buffering capacity to maintain pH value within local regions. It might be desirable to include some pH modifiers in the formu lation in order to temporarily modulate the microenviron ment at the application site for better drug absorption.
It is worth noting that pH can also influence the charge on the surface of the mucus, as well as certain ionizable groups of the polymers, wh ich might affect the strength of mucoadhesion. In addition, it has been shown that the pH of the mediu m influences the degree of hydration of crosslin ked poly(acry lic acid), e.g. polycarbophil [59] [60] . Therefore, the pH needs to be carefully chosen to optimize both drug permeat ion and mucoadhesion.
ORAL MUCOSA AS A BARRIER TO DRUG PERMEAB ILITY
A. Oral Mucosal epithelium as a barrier to permeability:
Oral mucosa containing epithelium acts as a protective layer for the tissues beneath and as a barrier to the entry of foreign material and microorganisms. However, oral mucosa is 4-4000 times more permeable than that of skin 61 .
The permeab ility barrier property of the oral mucosa is predominantly due to intercellu lar materials derived fro m the so-called membrane coating granules (M CGs) 8 . M CGs are spherical or oval organelles that are 100-300 n m in diameter and found in both keratin ized and non-keratinized epithelia. M CGs were first named as such because it was believed that they were subject to exocytosis from the cytoplasm of the stratum spinosum of keratin ized epithelia following thickening of these cells. Nonetheless, it is actually the contents of MCGs that are subject to exocytosis prior to the onset of membrane thickening.
MCGs are found near the upper, distal, or superficial border of the cells, and a few occur near the opposite border 62 and references therein). Several hypotheses have been suggested to describe the functions of MCGs, including a memb rane thicken ing effect, cell adhesion, production of a cell surface coat, cell desquamation, and permeab ility barrier. Hayward has reviewed the literature related to these functions, and it appears that the permeab ility barrier is most often attributed to MCGs 62 . They discharge their contents into the intercellular space to ensure epithelial cohesion in the superficial layers, and this discharge forms a barrier to the permeab ility of various compounds. Cultured oral epitheliu m devoid of MCGs has been shown to be permeable to compounds that do not typically penetrate oral ep itheliu m 63 . This same pattern is observed in both keratinized and nonkeratinized epithelia 8 , which indicates that keratinization of the epithelia, in and of it is not expected to play a major role as a barrier to permeat ion 64 .
B. Enzymes as a barrier to permeability
Another barrier to drug permeab ility across buccal epitheliu m is enzy mat ic degradation. Saliva contains no proteases, but does contain moderate levels of esterases, carbohydrases, and phosphatases 65 .
However, several proteolytic enzy mes have been found in the buccal epitheliu m 16 . Walker et al. 66 reported that endopeptidases and carboxypeptidases were not present on the surface of porcine buccal mucosa, whereas aminopeptidases appeared to be the major en zy matic barrier to the buccal delivery of peptide drugs. Aminopeptidase N and A (plasma memb rane-bound peptidases) and aminopeptidase B (cytosolic enzy me) have been found in the buccal tissue 67 . The use of mucoadhesive polymers as enzyme inhib itor agents has been developed to overcome this obstacle in peptide and protein delivery.
MUCOADHES IVE POLYMERS AS ENZYME INHIB ITORS AND PERMEATION ENHANCERS
It has been shown that some mucoadhesive polymers can act as an enzyme inhib itor. The particular importance of this finding lies in delivering therapeutic compounds that are specifically prone to extensive enzy matic degradation, such as protein and polypeptide drugs. Investigations have demonstrated that polymers, such as poly(acrylic acid), operate through a competitive mechanism with proteolytic enzy mes.
This stems from their strong affinity to divalent cations (Ca2+, Zn 2+) [68] [69] . These cations are essential cofactors for the metalloproteinases, such as trypsin.
Circular dichrois m studies suggest that Ca2+ depletion, med iated by the presence of some mucoadhesive polymers, causes the secondary structure of trypsin to change, and initiates a further autodegradation of the enzy me [68] [69] .
The increased intestinal permeability of various drugs in the presence of numerous mucoadhesive polymers has also been attributed to their ability to open up the tight junctions by absorbing the water fro m the epithelial cells. The result of water absorption by a dry and swellable polymer is dehydration of the cells and their subsequent shrinking. Th is potentially results in an expansion of the spaces between the cells (increased radius of the paracellu lar pathway) [70] [71] .
The use of multifunctional matrices, such as polyacrylates, cellu lose derivatives, and chitosan, that display mucoadhesive properties, permeation-enhancing effects, enzy me-inhibiting properties, and/or a high buffer capacity have proven successful strategies in oral drug delivery 72 . The inhibition of the major proteolytic enzy mes by these polymers is remarkab le and represents yet another possible approach for the delivery of therapeutic compounds, particularly protein and peptide drugs, through the buccal mucosa.
Any newly developed excip ients are likely to be subject to safety and toxicity testing to ensure the safety of these new-generation bioadhesive polymers.
Since lect ins are found in many species in the plant kingdom (e.g. tomato, wheat germ, mistletoe), they are not likely to be toxic. The fact that the source plants can be consumed raw, e.g. to mato fruit, would seem to suggest the safety of lectins. As mentioned previously, tomato lectin has been shown to bind to the surface of several cell monolayers, as well as rat intestinal epitheliu m without causing any harmfu l effects to the membranes. Another example is the clinical application of mistletoe lectin (Viscum albu m) for antitu mor therapy in rabbits and cancer patients 73 . To achieve the desired level of cytoadhesion, genetically engineered lectins or lectino mimetics with reduced toxicity/immunogenicity could also be used. In contrast, haemagglutinin fro m red kidney beans (Phaseolus vulgaris) and bacterial adhesive proteins might require more extensive testing.
Interestingly, thiolated compounds exhibited a significantly lower memb rane-damaging effect than the unmodified compounds after a 1-h incubation of rat red blood cells with a 0.025% solution of each compound. The lower membrane-damag ing effect of thiolated chitosan was attributed to the increased rigid ity of the molecule due to intra-and intermolecular d isulfide bonds, leading to reduced attachment to the cell memb rane.
An enhanced cytotoxicity of thio lated chitosan at concentrations of 0.25% and 0.5% was attributed to the increase in mo lecular weight and viscosity due to crosslinking via disulfide bond format ion. It was concluded that these thiolated compounds displayed a low cytotoxicity profile co mparable to that of the unmodified controls, which should not compromise their potential use in drug delivery. 
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Bioadhesive erodible buccal tablet for progesterone delivery 89 Natural oligosaccharide gum, M ucoadhesive buccal tablets for sustained release of salmon calcitonin 90 P(AA-co-EHA) Evaluation of P(AA-co-EHA) films for buccal mucoadhesive drug delivery 91 
HPC & CP
Used HPC-CP powder mixture as peripheral base for strong adhesion and HPC-CP freezedried mixture as core base 92 Cetylpyridinium chloride=CPC, SS F= S odium S tearylfumarate, P(AA-co-EHA)= Poly(acrylic acid-co-ethylhexyl acrylate), CP=Carbopol, PC=Polycarbophil, CC= Chitosan chloride
CONCLUS ION:
During the last few years research on buccal drug delivery has revealed considerable growth and advances. Among the various transepithelial sites available, the oral mucosa is the most convenient and accessible. If low drug concentrations are required to gain access to the blood, the transbuccal route may be very satisfactory, provided the physicochemical properties of a given drug allow permeat ion through the mucosa. Buccal mucosa allows drug delivery for both local and systemic therap ies.
Despite the advantages of delivering drugs through buccal mucosa, the formulat ive approach alone is not sufficient for an effective delivery control. The intrinsic physicochemical properties of the drug, such as solubility, partitioning, stability, crystallinity, thermodynamic activity, mo lecular size, pKa and half-life, can constitute limit ing factors to drug absorption. Therefore deep understanding of the various variables which affecting the delivery of drug through buccal mucosa is the most important considerations before designing of such drug delivery system.
